(Reuters) – Merrimack Pharmaceuticals Inc said its lead experimental cancer drug when used as a combination improved the overall survival rate in patients with metastatic pancreatic cancer, doubling its shares in premarket trading. Merrimack said a combination of its drug, MM-398, and…
Source:Merrimack cancer drug combination improves survival in study
Thursday, May 1, 2014
Merrimack cancer drug combination improves survival in study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment